conclude that “fluoxetine (alone or in combination with CBT [cognitive behavioural therapy]) seems to be the best choice for the acute treatment of moderate-to-severe depressive disorder in children and adolescents.” However, the meta-analysis has several statistical and methodological flaws that belie this and other conclusions.
First, the authors’ own data indicate that the conclusions about the superiority of fluoxetine are unjustifiable. Almost none of the comparisons between fluoxetine or fluoxetine plus CBT and other treatments are significant. Furthermore, the confidence intervals of most interventions versus pill placebo overlap with that of fluoxetine and fluoxetine plus CBT, indicating that none should be considered superior to any other.